The GABA/Diamyd® trial in the US now fully recruited
The placebo-controlled trial evaluating GABA in combination with Diamyd®, conducted at the University of Alabama at Birmingham in the U.S, is now fully recruited and has included 101 patients. Of these, 56 patients have already completed the entire trial. No serious side effects have been reported."The trial in Alabama is important in our commitment to GABA-based drugs in diabetes," says Ulf Hannelius, CEO of Diamyd Medical. “It gives us vital insights both regarding GABA:s therapeutic effects alone in type 1 diabetes as well as in combination with Diamyd®. Along with Remygen® and ongoing